Skip to main content
QNCX logo

QNCX

Quince Therapeutics, Inc.
$19.29 +2.04 (+11.83%) At close · Jul 14
Market Cap
$296.35M
Shares
16,300,740

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$19.29 Open$16.70 Day$16.23–19.98 52W$15.10–910.00 Avg vol 30d32K Short int113K · 0.7% float · 4.8d Short vol57% Last earningsAug 13, 2024 DataJan 2020–Jul 2026 Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 11, 2026
Equibles Rating blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 16.5 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −92%
below
Price vs 50-day avg −7%
below
RSI (14) 52
neutral
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Weak
1-month return +3%
trailing
6-month return −97%
trailing
YTD return −97%
this year
Relative strength −108%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $21 › 200d $237 — 200d above 50d
Institutional flow Distributing
-28% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.69% of float · ▼ -94.4% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
48 holders — mid 3-yr range
Squeeze score 50
elevated · 0–100
Fundamentals
Weak
EPS growth −28%
Y/Y
Free cash flow $-41.8M
Balance sheet $5.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 356%
annualized · 1-yr
Max drawdown −98%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−92% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $21 › 200d $237 — 200d above 50d
Institutional flow Distributing
-28% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.69% of float · ▼ -94.4% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
48 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $15 Now $19 · 0% 52-wk high $910
vs 200-day avg -92% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QNCX
Quince Therapeutics, Inc.
this stock
$296.35M -97.1% 0.7%
ONC
BeOne Medicines Ltd.
$443.06B +0.9% +22179.2% 901.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$120.89B +5.1% +46.2% 28.3 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$68.79B -14.9% +20.8% 16.0 3.3%
ARGX
Argenx SE
$53.96B +2.2% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
48
% held
93.9%
Net QoQ
-4.9M sh
Top holder
Woodline Partners LP
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Falling
Shares short
112.8K
Days to cover
4.8d
Change
-1.9M sh
View
Short Volume
Short vol %
57%
As of
Jul 14, 2026
Short Total
View
Fails to Deliver
FTD shares
26.9K
Value
$25.3K
As of
Jun 29, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-84.0M
EPS diluted
$-336.00
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 26, 2026
This year
17
View
Proposed Sales
Value
$173.2K
Shares
50.0K
Filed
Dec 29, 2025
View
Exempt Offerings
Offering
$186.4M
Filed
Jun 11, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 13, 2024
View
Investor Relations
Latest news
Quince Therapeutics Appoints Reco…
Published
Jun 30, 2026
View

Performance

5D 20D 120D MTD YTD
QNCX +10.2% +3.3% -97.2% +6.1% -97.1%
SPY +0.6% +1.4% +11.0% +0.7% +10.3%
vs SPY +9.7% +1.9% -108.1% +5.4% -107.4%
Key facts CIK 1662774 CUSIP 22053A206 13F (30d) 1 filings 1 filers Visit website Investor relations